SuperworthHalozyme Therapeutics HALO
- Market cap
- $14.3B
- PE
- 37.5×
- 6y median 21.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 8.6×
- EV/EBIT
- 17.4×
- Revenue, 12 months
- $1.7B
- +41% on a year ago
- Net margin
- 24.9%
- Free cash flow yield
- 5.7%
Halozyme Therapeutics trades at 37.5× trailing earnings, pricier than 88% of the last ten years. Revenue was $1.7B over the last twelve months, up 41% on a year earlier with a 25% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $216M+3% | $230M+27% | $195.9M+21% | $231.4M+5% | $290.1M+34% | $298M+30% | $264.9M+35% | $325.7M+41% | $354.3M+22% | $451.8M+52% | $376.7M+42% | $481M+48% | |
| Cost of revenue | $54.8M+16% | $52.3M+24% | $28.3M−20% | $39.6M−21% | $49.4M−10% | $42.1M−20% | $48.4M+71% | $46.4M+17% | $55.2M+12% | $78.8M+87% | $79.2M+64% | $79.2M+71% |
| Gross profit | $161.2M−0% | $177.7M+28% | $167.6M+32% | $191.7M+12% | $240.7M+49% | $256M+44% | $216.5M+29% | $279.4M+46% | $299M+24% | $373M+46% | $297.5M+37% | $401.8M+44% |
| R&D | $17.3M+4% | $21.3M−6% | $19.1M+6% | $21M+7% | $18.5M+7% | $20.4M−4% | $14.8M−23% | $17.5M−17% | $17.3M−7% | $31.9M+56% | $25.6M+73% | $27.7M+58% |
| SG&A | $35.3M+2% | $37.6M−0% | $35.1M−6% | $35.7M−8% | $41.2M+17% | $42.2M+12% | $42.4M+21% | $41.6M+17% | $46.1M+12% | $77M+82% | $57.9M+37% | $57M+37% |
| $88.3M+6% | $101M+36% | $95.5M+78% | $117.2M+24% | $163.2M+85% | $175.5M+74% | $141.5M+48% | $202.4M+73% | $217.9M+34% | −$92.9M | $184.5M+30% | $287.7M+42% | |
| Interest expense | $4.5M−40% | $5.2M+14% | $4.5M−1% | $4.5M+1% | $4.5M+0% | $4.5M−13% | $4.5M+0% | $4.4M−3% | $4.3M−5% | $4.9M+8% | $5.5M+22% | $5.6M+27% |
| Pre-tax income | $101.8M+38% | $101.2M+43% | $96M+84% | $117.7M+26% | $165.1M+62% | $178.2M+76% | $143.8M+50% | $204.9M+74% | $219M+33% | −$100.8M | $180.3M+25% | $284.9M+39% |
| $19.9M+65% | $15.8M+21% | $19.2M+52% | $24.5M+33% | $28.1M+41% | $41.2M+161% | $25.7M+34% | $39.8M+62% | $43.7M+55% | $40.7M−1% | $30.3M+18% | $55M+38% | |
| Net income | $81.8M+33% | $85.4M+48% | $76.8M+94% | $93.2M+25% | $137M+67% | $137M+61% | $118.1M+54% | $165.2M+77% | $175.2M+28% | −$141.6M | $150M+27% | $229.9M+39% |
| $0.61+39% | $0.65+59% | $0.60+107% | $0.72+29% | $1.05+72% | $1.06+63% | $0.93+55% | $1.33+85% | $1.43+36% | −$1.20 | $1.22+31% | $1.90+43% | |
| 134.1M−4% | 131.1M−6% | 128.9M−7% | 129.2M−3% | 130.1M−3% | 129.1M−2% | 126.6M−2% | 124.2M−4% | 122.3M−6% | 117.7M−9% | 122.9M−3% | 121.2M−2% |
Gross profit: 36 periods, Q3 FY17 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY21 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| Peer median | $19.7B | 29.4× | 42.8× | 26.7× | 6.8× | +20% | 24.3% |
More on Halozyme Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 18Biotech stocks with the highest free cash flow yield
- #9of 29Biotech stocks with the highest profit margins
- #8of 17Biotech stocks with the lowest EV/EBIT
- #10of 16Biotech stocks with the lowest PE ratio
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .